{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T15:31:16Z","timestamp":1782833476524,"version":"3.54.5"},"reference-count":254,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T00:00:00Z","timestamp":1682467200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003621","name":"Ministry of Science, ICT and Future Planning","doi-asserted-by":"publisher","award":["CAP-21022-000"],"award-info":[{"award-number":["CAP-21022-000"]}],"id":[{"id":"10.13039\/501100003621","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003718","name":"Korea Institute of Oriental Medicine","doi-asserted-by":"publisher","award":["KSN1822320"],"award-info":[{"award-number":["KSN1822320"]}],"id":[{"id":"10.13039\/501100003718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008783","name":"National Research Council of Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008783","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine &amp; Pharmacotherapy"],"published-print":{"date-parts":[[2023,7]]},"DOI":"10.1016\/j.biopha.2023.114802","type":"journal-article","created":{"date-parts":[[2023,5,3]],"date-time":"2023-05-03T14:25:58Z","timestamp":1683123958000},"page":"114802","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1"],"prefix":"10.1016","volume":"163","author":[{"given":"Subramanian","family":"Muthamil","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun Yong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hyun-Jun","family":"Jang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji-Hyo","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ung Cheol","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Younghoon","family":"Go","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seong-Hoon","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hee Gu","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun Hong","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib1","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.cmet.2012.06.011","article-title":"Cancer cachexia: mediators, signaling, and metabolic pathways","volume":"16","author":"Fearon","year":"2012","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib2","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1478271520093903002","article-title":"What is cancer anorexia-cachexia syndrome? A historical perspective","volume":"39","author":"Bennani-Baiti","year":"2009","journal-title":"J. R. Coll. Physicians Edinb."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib3","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","article-title":"Definition and classification of cancer cachexia: an international consensus","volume":"12","author":"Fearon","year":"2011","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib4","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/s41568-020-0251-4","article-title":"Understanding cachexia in the context of metastatic progression","volume":"20","author":"Biswas","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib5","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nrclinonc.2012.209","article-title":"Understanding the mechanisms and treatment options in cancer cachexia","volume":"10","author":"Fearon","year":"2013","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib6","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1002\/jcsm.12167","article-title":"Prevalence and clinical impact of cachexia in chronic illness in Europe, USA, and Japan: facts and numbers update 2016","volume":"7","author":"Von Haehling","year":"2016","journal-title":"J. Cachex Sarcopenia Muscle"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib7","first-page":"1","article-title":"Cancer-associated cachexia","volume":"4","author":"Baracos","year":"2018","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2023.114802_bib8","first-page":"6389","article-title":"Bile acid dysregulation is intrinsically related to cachexia in tumor-bearing mice","volume":"13","author":"Thibaut","year":"2021","journal-title":"Cancers 2022"},{"key":"10.1016\/j.biopha.2023.114802_bib9","doi-asserted-by":"crossref","first-page":"5597","DOI":"10.2147\/CMAR.S261585","article-title":"Cancer cachexia: definition, staging, and emerging treatments","volume":"12","author":"Ni","year":"2020","journal-title":"Cancer Manag. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib10","doi-asserted-by":"crossref","first-page":"3","DOI":"10.21037\/apm.2018.12.01","article-title":"Cancer cachexia is defined by an ongoing loss of skeletal muscle mass","volume":"8","author":"Baracos","year":"2019","journal-title":"Ann. Palliat. Med."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib11","doi-asserted-by":"crossref","DOI":"10.15252\/embr.201847258","article-title":"Energy metabolism in cachexia","volume":"20","author":"Rohm","year":"2019","journal-title":"EMBO Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib12","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41574-018-0123-0","article-title":"Inter-tissue communication in cancer cachexia","volume":"15","author":"Argil\u00e9s","year":"2019","journal-title":"Nat. Rev. Endocrinol."},{"issue":"25","key":"10.1016\/j.biopha.2023.114802_sbref13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1016\/0024-3205(91)90292-J","article-title":"Preferential loss of body fat during starvation in dietary obese rats","volume":"49","author":"Hill","year":"1991","journal-title":"Life Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_sbref14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib14","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1093\/ajcn\/83.4.735","article-title":"Cachexia: pathophysiology and clinical relevance","volume":"83","author":"Morley","year":"2006","journal-title":"Am. J. Clin. Nutr."},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib15","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S2213-8587(14)70034-8","article-title":"Age-related and disease-related muscle loss: the effect of diabetes, obesity, and other diseases","volume":"2","author":"Kalyani","year":"2014","journal-title":"Lancet Diabetes Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib16","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.cmet.2019.06.008","article-title":"Aerobic plus resistance exercise in obese older adults improves muscle protein synthesis and preserves myocellular quality despite weight loss","volume":"30","author":"Colleluori","year":"2019","journal-title":"Cell Metab."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.jamda.2011.01.003","article-title":"Sarcopenia: an undiagnosed condition in older adults. Current consensus definition: prevalence, etiology, and consequences. International working group on sarcopenia","volume":"12","author":"Fielding","year":"2011","journal-title":"J. Am. Med. Dir. Assoc."},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib18","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/s41574-018-0062-9","article-title":"Sarcopenic obesity in older adults: aetiology, epidemiology and treatment strategies","volume":"14","author":"Batsis","year":"2018","journal-title":"Nat. Rev. Endocrinol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib19","first-page":"46","article-title":"Reversing sarcopenia: how weight training can build strength and vitality","volume":"51","author":"Evans","year":"1996","journal-title":"Geriatrics (Basel, Switzerland)"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib20","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3390\/ijms17010124","article-title":"Molecular regulation of adipogenesis and potential anti-adipogenic bioactive molecules","volume":"17","author":"Moseti","year":"2016","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0121971","article-title":"Inflammatory cytokines in general and central obesity and modulating effects of physical activity","volume":"10","author":"Schmidt","year":"2015","journal-title":"PloS One"},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib22","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.3390\/ijms21124283","article-title":"Adipogenesis: a complex interplay of multiple molecular determinants and pathways","volume":"21","author":"Ambele","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.114802_bib23","first-page":"1","article-title":"Beta-naphthoflavone increases the differentiation of osteoblasts and suppresses adipogenesis in human adipose derived stem cells involving STAT3 pathway","author":"Lu","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"key":"10.1016\/j.biopha.2023.114802_bib24","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1002\/j.2040-4603.2017.tb00753.x","article-title":"Transcriptional regulation of adipogenesis","volume":"7","author":"Mota de S\u00e1","year":"2017","journal-title":"Compr. Physiol."},{"key":"10.1016\/j.biopha.2023.114802_bib25","first-page":"1","article-title":"Adipogenic effects of Ostreae Testa water extract on white adipocytes","author":"Lee","year":"2023","journal-title":"Mol. Cell. Toxicol."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2023.114802_bib26","first-page":"93","article-title":"A study of genes involved in adipocyte differentiation","volume":"28","author":"Zhu","year":"2015","journal-title":"J. Pediatr. Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib27","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.devcel.2013.07.002","article-title":"A multifunctional protein, EWS, is essential for early brown fat lineage determination","volume":"26","author":"Park","year":"2013","journal-title":"Dev. Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib28","doi-asserted-by":"crossref","first-page":"33","DOI":"10.4252\/wjsc.v6.i1.33","article-title":"Distinction of white, beige and brown adipocytes derived from mesenchymal stem cells","volume":"6","author":"Park","year":"2014","journal-title":"World J. Stem Cells"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib29","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1152\/physrev.00015.2003","article-title":"Brown adipose tissue: function and physiological significance","volume":"84","author":"Cannon","year":"2004","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.biopha.2023.114802_bib30","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3389\/fendo.2015.00124","article-title":"Intricate transcriptional networks of classical brown and beige fat cells","volume":"6","author":"Park","year":"2015","journal-title":"Front. Endocrinol."},{"key":"10.1016\/j.biopha.2023.114802_bib31","doi-asserted-by":"crossref","DOI":"10.1152\/ajpendo.00250.2013","article-title":"An endocrine role for brown adipose tissue?","author":"Villarroya","year":"2013","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib32","first-page":"1691","article-title":"Contrasting effects of cold acclimation versus obesogenic diets on chemerin gene expression in brown and brite adipose tissues","volume":"1841","author":"Hansen","year":"2014","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Mol. Cell Biol. Lipids"},{"key":"10.1016\/j.biopha.2023.114802_bib33","doi-asserted-by":"crossref","first-page":"E444","DOI":"10.1152\/ajpendo.00691.2006","article-title":"Unexpected evidence for active brown adipose tissue in adult humans","volume":"293","author":"Nedergaard","year":"2007","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib34","doi-asserted-by":"crossref","first-page":"E1085","DOI":"10.1152\/ajpendo.00023.2015","article-title":"A stringent validation of mouse adipose tissue identity markers","volume":"308","author":"de Jong","year":"2015","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.tcb.2016.01.004","article-title":"Emerging complexities in adipocyte origins and identity","volume":"26","author":"Sanchez-Gurmaches","year":"2016","journal-title":"Trends Cell Biol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib36","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.0020146","article-title":"Adenomatous polyposis coli (APC) is required for normal development of skin and thymus","volume":"2","author":"Kuraguchi","year":"2006","journal-title":"PLoS Genet."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib37","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1016\/j.ccr.2005.04.023","article-title":"Trp53R172H and KrasG12D cooperate to promote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice","volume":"7","author":"Hingorani","year":"2005","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.biopha.2023.114802_bib38","first-page":"2290","article-title":"Experimental cancer cachexia induced by transplantable colon 26 adenocarcinoma in mice","volume":"50","author":"Tanaka","year":"1990","journal-title":"Cancer Res."},{"issue":"8","key":"10.1016\/j.biopha.2023.114802_bib39","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1096\/fasebj.3.8.2721856","article-title":"Anticachectin\/tumor necrosis factor\u2010\u03b1 antibodies attenuate development of cachexia in tumor models","volume":"3","author":"Sherry","year":"1989","journal-title":"FASEB J."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib40","doi-asserted-by":"crossref","first-page":"90","DOI":"10.3390\/cancers14010090","article-title":"Aging aggravates cachexia in tumor-bearing mice","volume":"14","author":"Geppert","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.biopha.2023.114802_bib41","series-title":"Animal Models in Cancer Drug Discovery","first-page":"59","article-title":"Animal models of cancer-associated cachexia","author":"Shukla","year":"2019"},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib42","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41401-019-0275-z","article-title":"Establishment of a mouse model of cancer cachexia with spleen deficiency syndrome and the effects of atractylenolide I","volume":"41","author":"Zhang","year":"2020","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1080\/17460441.2020.1724954","article-title":"Promising models for cancer-induced cachexia drug discovery","volume":"15","author":"Suzuki","year":"2020","journal-title":"Expert Opin. Drug Discov."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib44","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1016\/j.celrep.2019.07.016","article-title":"Modeling human cancer-induced cachexia","volume":"28","author":"Talbert","year":"2019","journal-title":"Cell Rep."},{"issue":"16","key":"10.1016\/j.biopha.2023.114802_bib45","doi-asserted-by":"crossref","first-page":"3999","DOI":"10.1158\/1078-0432.CCR-16-0495","article-title":"Molecular Pathways: Cachexia Signaling\u2014A Targeted Approach to Cancer Treatment","volume":"22","author":"Miyamoto","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib46","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.lfs.2016.11.033","article-title":"TNF-\u03b1 and cancer cachexia: Molecular insights and clinical implications","volume":"170","author":"Patel","year":"2017","journal-title":"Life Sci."},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib47","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1002\/cncr.23802","article-title":"Lipolysis\u2014not inflammation, cell death, or lipogenesis\u2014is involved in adipose tissue loss in cancer cachexia","volume":"113","author":"Ryd\u00e9n","year":"2008","journal-title":"Cancer: Interdiscip. Int. J. Am. Cancer Soc."},{"issue":"17","key":"10.1016\/j.biopha.2023.114802_bib48","doi-asserted-by":"crossref","first-page":"2671","DOI":"10.3390\/cells11172671","article-title":"Transforming growth factor-beta signaling in cancer-induced cachexia: from molecular pathways to the clinics","volume":"11","author":"Balsano","year":"2022","journal-title":"Cells"},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib49","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1002\/jcsm.12441","article-title":"Tumour\u2010derived transforming growth factor\u2010\u03b2 signalling contributes to fibrosis in patients with cancer cachexia","volume":"10","author":"Lima","year":"2019","journal-title":"J. Cachex, Sarcopenia Muscle"},{"key":"10.1016\/j.biopha.2023.114802_bib50","first-page":"130","article-title":"Serum levels of tumour necrosis factor alpha and other cytokines do not correlate with weight loss and anorexia in cancer patients","volume":"5","author":"Maltoni","year":"1997","journal-title":"Support. Care Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib51","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1002\/cncr.22944","article-title":"A placebo-controlled double blind trial of etanercept for the cancer anorexia\/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group","volume":"110","author":"Jatoi","year":"2007","journal-title":"Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib52","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.lungcan.2009.06.020","article-title":"A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and\/or poor performance non-small cell lung cancer patients (N01C9)","volume":"68","author":"Jatoi","year":"2010","journal-title":"Lung Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib53","doi-asserted-by":"crossref","first-page":"E410","DOI":"10.1152\/ajpendo.00039.2012","article-title":"JAK\/STAT3 pathway inhibition blocks skeletal muscle wasting downstream of IL-6 and in experimental cancer cachexia","volume":"303","author":"Bonetto","year":"2012","journal-title":"Am. J. Physiol. -Endocrinol. Metab."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib54","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/SPC.0000000000000091","article-title":"Role of IL-6 in cachexia\u2013therapeutic implications","volume":"8","author":"Narsale","year":"2014","journal-title":"Curr. Opin. Support. Palliat. Care"},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib55","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/S1470-2045(14)70155-X","article-title":"MABp1, a first-in-class true human antibody targeting interleukin-1\u03b1 in refractory cancers: an open-label, phase 1 dose-escalation and expansion study","volume":"15","author":"Hong","year":"2014","journal-title":"Lancet Oncol."},{"issue":"15_suppl","key":"10.1016\/j.biopha.2023.114802_bib56","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2009.27.15_suppl.3025","article-title":"A phase I, pharmacokinetic (PK), and preliminary efficacy assessment of ALD518, a humanized anti-IL-6 antibody, in patients with advanced cancer","volume":"27","author":"Clarke","year":"2009","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.biopha.2023.114802_bib57","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.7622","article-title":"Efect of ALD518, a humanized anti-IL-6 antibody, on lean body mass loss and symptoms in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II randomized, double-blind safety and efficacy trial","volume":"28","author":"Rigas","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"15_suppl","key":"10.1016\/j.biopha.2023.114802_bib58","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2010.28.15_suppl.7631","article-title":"ALD518, a humanized anti-IL-6 antibody, treats anemia in patients with advanced non-small cell lung cancer (NSCLC): Results of a phase II, randomized, double-blind, placebo-controlled trial","volume":"28","author":"Schuster","year":"2010","journal-title":"J. Clin. Oncol."},{"issue":"6628","key":"10.1016\/j.biopha.2023.114802_bib59","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1038\/387083a0","article-title":"Regulation of skeletal muscle mass in mice by a new TGF-p superfamily member","volume":"387","author":"McPherron","year":"1997","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114802_bib60","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s10555-006-9006-2","article-title":"Transforming growth factor-\u03b2 in cancer and metastasis","volume":"25","author":"Jakowlew","year":"2006","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.biopha.2023.114802_bib61","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1007\/s12094-009-0433-8","article-title":"Role of transforming growth factor \u03b2 in cancer microenvironment","volume":"11","author":"de la Cruz-Merino","year":"2009","journal-title":"Clin. Transl. Oncol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib62","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.tem.2014.06.002","article-title":"TGF\u03b2 and BMP signaling in skeletal muscle: potential significance for muscle-related disease","volume":"25","author":"Sartori","year":"2014","journal-title":"Trends Endocrinol. Metab."},{"issue":"26","key":"10.1016\/j.biopha.2023.114802_bib63","doi-asserted-by":"crossref","first-page":"E5266","DOI":"10.1073\/pnas.1620013114","article-title":"Specific targeting of TGF-\u03b2 family ligands demonstrates distinct roles in the regulation of muscle mass in health and disease","volume":"114","author":"Chen","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib64","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132786","article-title":"TGF-\u03b2 blockade reduces mortality and metabolic changes in a validated murine model of pancreatic cancer cachexia","volume":"10","author":"Greco","year":"2015","journal-title":"PloS One"},{"issue":"19","key":"10.1016\/j.biopha.2023.114802_bib65","doi-asserted-by":"crossref","first-page":"6118","DOI":"10.1158\/1078-0432.CCR-11-0482","article-title":"The two faces of interferon-\u03b3 in cancerthe two faces of IFN-\u03b3","volume":"17","author":"Zaidi","year":"2011","journal-title":"Clin. Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib66","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/ni.2212","article-title":"Cellular teamwork in antibacterial innate immunity","volume":"13","author":"Ayres","year":"2012","journal-title":"Nat. Immunol."},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib67","doi-asserted-by":"crossref","first-page":"4509","DOI":"10.1002\/cam4.1700","article-title":"Interferon gamma in cancer immunotherapy","volume":"7","author":"Ni","year":"2018","journal-title":"Cancer Med."},{"key":"10.1016\/j.biopha.2023.114802_bib68","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0065-230X(08)00407-7","article-title":"IFN inducibility of major histocompatibility antigens in tumors","volume":"101","author":"Seliger","year":"2008","journal-title":"Adv. Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib69","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1476-4598-13-129","article-title":"MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress","volume":"13","author":"Felder","year":"2014","journal-title":"Mol. Cancer"},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib70","doi-asserted-by":"crossref","first-page":"14871","DOI":"10.18632\/oncotarget.7652","article-title":"Tumor necrosis factor-\u03b1 and interferon-\u03b3 stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NF\u03baB","volume":"7","author":"Morgado","year":"2016","journal-title":"Oncotarget"},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib71","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1038\/sj.bjc.6606083","article-title":"Enhanced ZAG production by subcutaneous adipose tissue is linked to weight loss in gastrointestinal cancer patients","volume":"104","author":"Mracek","year":"2011","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib72","doi-asserted-by":"crossref","first-page":"4727","DOI":"10.1096\/fj.201701465RR","article-title":"The tumor secretory factor ZAG promotes white adipose tissue browning and energy wasting","volume":"32","author":"Elattar","year":"2018","journal-title":"FASEB J."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib73","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1038\/sj.bjc.6600086","article-title":"Role of \u03b23-adrenergic receptors in the action of a tumour lipid mobilizing factor","volume":"86","author":"Russell","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib74","first-page":"2405","article-title":"Increased gene expression of brown fat uncoupling protein (UCP) 1 and skeletal muscle UCP2 and UCP3 in MAC16-induced cancer cachexia","volume":"60","author":"Bing","year":"2000","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib75","doi-asserted-by":"crossref","first-page":"298","DOI":"10.3389\/fonc.2020.00298","article-title":"Management of cancer cachexia: attempting to develop new pharmacological agents for new effective therapeutic options","volume":"10","author":"Marceca","year":"2020","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib76","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/j.cmet.2015.11.003","article-title":"PTH\/PTHrP receptor mediates cachexia in models of kidney failure and cancer","volume":"23","author":"Kir","year":"2016","journal-title":"Cell Metab."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib77","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.cmet.2014.06.011","article-title":"A switch from white to brown fat increases energy expenditure in cancer-associated cachexia","volume":"20","author":"Petruzzelli","year":"2014","journal-title":"Cell Metab."},{"issue":"7516","key":"10.1016\/j.biopha.2023.114802_bib78","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nature13528","article-title":"Tumour-derived PTH-related protein triggers adipose tissue browning and cancer cachexia","volume":"513","author":"Kir","year":"2014","journal-title":"Nature"},{"issue":"11","key":"10.1016\/j.biopha.2023.114802_bib79","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1172\/JCI118698","article-title":"Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism","volume":"97","author":"Brink","year":"1996","journal-title":"J. Clin. Investig."},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib80","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1016\/j.biocel.2013.05.035","article-title":"Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia","volume":"45","author":"Yoshida","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.biopha.2023.114802_bib81","first-page":"245","article-title":"The renin-angiotensin system and the biology of skeletal muscle: Mechanisms of muscle wasting in chronic disease states","volume":"127","author":"Delafontaine","year":"2016","journal-title":"Trans. Am. Clin. Climatol. Assoc."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib82","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1161\/HYPERTENSIONAHA.111.174839","article-title":"Angiotensin II upregulates protein phosphatase 2C\u03b1 and inhibits AMP-activated protein kinase signaling and energy balance leading to skeletal muscle wasting","volume":"58","author":"Tabony","year":"2011","journal-title":"Hypertension"},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib83","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1002\/cncr.21013","article-title":"Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care\u2014correlations with food intake, metabolism, exercise capacity, and hormones","volume":"103","author":"Fouladiun","year":"2005","journal-title":"Cancer: Interdiscip. Int. J. Am. Cancer Soc."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib84","first-page":"233","article-title":"Epigenetic drugs in the treatment of skeletal muscle atrophy","volume":"11","author":"Guasconi","year":"2008","journal-title":"Curr. Opin. Clin. Nutr. Metab. care"},{"key":"10.1016\/j.biopha.2023.114802_bib85","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s13539-011-0029-3","article-title":"IGF-1 treatment reduces weight loss and improves outcome in a rat model of cancer cachexia","volume":"2","author":"Schmidt","year":"2011","journal-title":"J. Cachex, Sarcopenia Muscle"},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib86","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1002\/ijc.25146","article-title":"Muscle atrophy in experimental cancer cachexia: is the IGF\u20101 signaling pathway involved?","volume":"127","author":"Penna","year":"2010","journal-title":"Int. J. Cancer"},{"issue":"17","key":"10.1016\/j.biopha.2023.114802_bib87","doi-asserted-by":"crossref","first-page":"9469","DOI":"10.3390\/ijms22179469","article-title":"IGF-1 and IGFBP-3 in Inflammatory Cachexia","volume":"22","author":"Mart\u00edn","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib88","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1038\/nrc2853","article-title":"TGF\u03b2 signalling: a complex web in cancer progression","volume":"10","author":"Ikushima","year":"2010","journal-title":"Nat. Rev. Cancer"},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib89","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S1097-2765(03)00386-1","article-title":"Activin receptor-like kinase (ALK) 1 is an antagonistic mediator of lateral TGF\u03b2\/ALK5 signaling","volume":"12","author":"Goumans","year":"2003","journal-title":"Mol. Cell"},{"issue":"22","key":"10.1016\/j.biopha.2023.114802_bib90","doi-asserted-by":"crossref","first-page":"6889","DOI":"10.1128\/MCB.01192-08","article-title":"Transforming growth factor \u03b2-induced Smad1\/5 phosphorylation in epithelial cells is mediated by novel receptor complexes and is essential for anchorage-independent growth","volume":"28","author":"Daly","year":"2008","journal-title":"Mol. Cell. Biol."},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib91","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1046\/j.1365-2443.2002.00599.x","article-title":"Two major Smad pathways in TGF-\u03b2 superfamily signalling","volume":"7","author":"Miyazawa","year":"2002","journal-title":"Genes Cells"},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib92","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0092-8674(03)00432-X","article-title":"Mechanisms of TGF-\u03b2 signaling from cell membrane to the nucleus","volume":"113","author":"Shi","year":"2003","journal-title":"Cell"},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib93","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.3390\/ijms21103534","article-title":"SMAD4 and the TGF\u03b2 pathway in patients with pancreatic ductal adenocarcinoma","volume":"21","author":"Dardare","year":"2020","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib94","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/j.cell.2016.01.009","article-title":"TGF-\u03b2 tumor suppression through a lethal EMT","volume":"164","author":"David","year":"2016","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib95","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.cell.2016.06.028","article-title":"EMT: 2016","volume":"166","author":"Nieto","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114802_bib96","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s12029-018-00195-5","article-title":"TGF-\u03b2 inhibitors in metastatic pancreatic ductal adenocarcinoma","volume":"50","author":"Alvarez","year":"2019","journal-title":"J. Gastrointest. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib97","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/jcsm.12037","article-title":"Cachexia-associated adipose tissue morphological rearrangement in gastrointestinal cancer patients","volume":"7","author":"Batista","year":"2016","journal-title":"J. Cachex Sarcopenia Muscle"},{"key":"10.1016\/j.biopha.2023.114802_bib98","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12885-017-3178-8","article-title":"Adipose tissue fibrosis in human cancer cachexia: the role of TGF\u03b2 pathway","volume":"17","author":"Alves","year":"2017","journal-title":"BMC Cancer"},{"key":"10.1016\/j.biopha.2023.114802_bib99","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.euprot.2015.06.004","article-title":"Transforming growth factor-\u03b2, MAPK and Wnt signaling interactions in colorectal cancer","volume":"8","author":"Cheruku","year":"2015","journal-title":"EuPA Open Proteom."},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib100","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1210\/en.2006-0089","article-title":"Biological activity of follistatin isoforms and follistatin-like-3 is dependent on differential cell surface binding and specificity for activin, myostatin, and bone morphogenetic proteins","volume":"147","author":"Sidis","year":"2006","journal-title":"Endocrinology"},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib101","doi-asserted-by":"crossref","first-page":"2333","DOI":"10.1016\/j.biocel.2013.05.019","article-title":"Myostatin\/activin pathway antagonism: molecular basis and therapeutic potential","volume":"45","author":"Han","year":"2013","journal-title":"Int. J. Biochem. Cell Biol."},{"issue":"51","key":"10.1016\/j.biopha.2023.114802_bib102","doi-asserted-by":"crossref","first-page":"49831","DOI":"10.1074\/jbc.M204291200","article-title":"Myostatin inhibits myoblast differentiation by down-regulating MyoD expression","volume":"277","author":"Langley","year":"2002","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib103","doi-asserted-by":"crossref","first-page":"C195","DOI":"10.1152\/ajpcell.00012.2011","article-title":"Human myostatin negatively regulates human myoblast growth and differentiation","volume":"301","author":"McFarlane","year":"2011","journal-title":"Am. J. Physiol. -Cell Physiol."},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib104","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1016\/j.tcb.2005.10.007","article-title":"Stem cells in postnatal myogenesis: molecular mechanisms of satellite cell quiescence, activation and replenishment","volume":"15","author":"Dhawan","year":"2005","journal-title":"Trends Cell Biol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib105","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.stem.2007.12.012","article-title":"Niche regulation of muscle satellite cell self-renewal and differentiation","volume":"2","author":"Kuang","year":"2008","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.biopha.2023.114802_bib106","first-page":"1","article-title":"The local control of the pituitary by activin signaling and modulation","volume":"4","author":"Bilezikjian","year":"2011","journal-title":"Open Neuroendocrinol. J."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib107","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1016\/S0002-9440(10)62047-0","article-title":"Activin controls skin morphogenesis and wound repair predominantly via stromal cells and in a concentration-dependent manner via keratinocytes","volume":"167","author":"Bamberger","year":"2005","journal-title":"Am. J. Pathol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib108","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9440(10)63216-6","article-title":"Activin a in the regulation of corneal neovascularization and vascular endothelial growth factor expression","volume":"164","author":"Poulaki","year":"2004","journal-title":"Am. J. Pathol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib109","doi-asserted-by":"crossref","first-page":"168","DOI":"10.4161\/cc.5.2.2341","article-title":"Control of hepatic differentiation by activin\/TGF\u03b2 signaling","volume":"5","author":"Clotman","year":"2006","journal-title":"Cell Cycle"},{"issue":"1\u20132","key":"10.1016\/j.biopha.2023.114802_bib110","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0303-7207(01)00515-9","article-title":"Antagonism of activin by inhibin and inhibin receptors: a functional role for betaglycan-glycan","volume":"180","author":"Gray","year":"2001","journal-title":"Mol. Cell. Endocrinol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib111","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1530\/rep.1.01073","article-title":"Pituitary actions of ligands of the TGF-\u03b2 family: activins and inhibins","volume":"132","author":"Bilezikjian","year":"2006","journal-title":"Reproduction"},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib112","first-page":"1095","article-title":"Nucleotide sequence and expression of a cDNA encoding MyD88, a novel myeloid differentiation primary response gene induced by IL6","volume":"5","author":"Lord","year":"1990","journal-title":"Oncogene"},{"issue":"6325","key":"10.1016\/j.biopha.2023.114802_bib113","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/351355b0","article-title":"Drosophila Toll and IL-1 receptor","volume":"351","author":"Gay","year":"1991","journal-title":"Nature"},{"key":"10.1016\/j.biopha.2023.114802_bib114","first-page":"6","article-title":"MyD88: a central player in innate immune signaling","author":"Deguine","year":"2014","journal-title":"F1000prime Rep."},{"key":"10.1016\/j.biopha.2023.114802_bib115","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1007\/s10787-019-00592-7","article-title":"Neuroprotective and anti-inflammatory effects of isoliquiritigenin in kainic acid-induced epileptic rats via the TLR4\/MYD88 signaling pathway","volume":"27","author":"Zhu","year":"2019","journal-title":"Inflammopharmacology"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib116","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1038\/s41467-017-01866-w","article-title":"MyD88 promotes myoblast fusion in a cell-autonomous manner","volume":"8","author":"Hindi","year":"2017","journal-title":"Nat. Commun."},{"issue":"15","key":"10.1016\/j.biopha.2023.114802_bib117","doi-asserted-by":"crossref","first-page":"e00184","DOI":"10.1128\/MCB.00184-19","article-title":"The toll-like receptor\/MyD88\/XBP1 signaling axis mediates skeletal muscle wasting during cancer cachexia","volume":"39","author":"Bohnert","year":"2019","journal-title":"Mol. Cell. Biol."},{"issue":"16","key":"10.1016\/j.biopha.2023.114802_bib118","doi-asserted-by":"crossref","first-page":"1983","DOI":"10.1101\/gad.14.16.1983","article-title":"HIF-1 and human disease: one highly involved factor","volume":"14","author":"Semenza","year":"2000","journal-title":"Genes Dev."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib119","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1016\/j.apsb.2015.05.007","article-title":"HIF-1\u03b1 pathway: role, regulation and intervention for cancer therapy","volume":"5","author":"Masoud","year":"2015","journal-title":"Acta Pharm. Sin. B"},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib120","doi-asserted-by":"crossref","first-page":"5510","DOI":"10.1073\/pnas.92.12.5510","article-title":"Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2 tension","volume":"92","author":"Wang","year":"1995","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6863","key":"10.1016\/j.biopha.2023.114802_bib121","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1038\/35107085","article-title":"Inhibitory PAS domain protein is a negative regulator of hypoxia-inducible gene expression","volume":"414","author":"Makino","year":"2001","journal-title":"Nature"},{"issue":"35","key":"10.1016\/j.biopha.2023.114802_bib122","doi-asserted-by":"crossref","first-page":"21262","DOI":"10.1074\/jbc.271.35.21262","article-title":"Induction of phosphoglycerate kinase 1 gene expression by hypoxia: Roles of ARNT and HIF1\u03b1","volume":"271","author":"Li","year":"1996","journal-title":"J. Biol. Chem."},{"issue":"16","key":"10.1016\/j.biopha.2023.114802_bib123","doi-asserted-by":"crossref","first-page":"12645","DOI":"10.1074\/jbc.M011344200","article-title":"Molecular regulation of the endothelin-1 gene by hypoxia: contributions of hypoxia-inducible factor-1, activator protein-1, GATA-2, and p300\/CBP","volume":"276","author":"Yamashita","year":"2001","journal-title":"J. Biol. Chem."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib124","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.bbcan.2005.05.001","article-title":"Negative and positive regulation of HIF-1: a complex network","volume":"1755","author":"B\u00e1rdos","year":"2005","journal-title":"Biochim. Et. Biophys. Acta (BBA)-Rev. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib125","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.bbrc.2005.08.111","article-title":"Signalling hypoxia by HIF hydroxylases","volume":"338","author":"Schofield","year":"2005","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib126","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.cardiores.2006.05.005","article-title":"Regulating cellular oxygen sensing by hydroxylation","volume":"71","author":"Fandrey","year":"2006","journal-title":"Cardiovasc. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib127","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3390\/cancers13010159","article-title":"Ways into understanding HIF inhibition","volume":"13","author":"Sch\u00f6nberger","year":"2021","journal-title":"Cancers"},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib128","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.molcel.2008.04.009","article-title":"Oxygen sensing by metazoans: the central role of the HIF hydroxylase pathway","volume":"30","author":"Kaelin","year":"2008","journal-title":"Mol. Cell"},{"issue":"11","key":"10.1016\/j.biopha.2023.114802_bib129","doi-asserted-by":"crossref","first-page":"5703","DOI":"10.3390\/ijms22115703","article-title":"Cancer cell metabolism in hypoxia: Role of HIF-1 as key regulator and therapeutic target","volume":"22","author":"Infantino","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib130","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/S0092-8674(02)01085-1","article-title":"Regulation and destabilization of HIF-1\u03b1 by ARD1-mediated acetylation","volume":"111","author":"Jeong","year":"2002","journal-title":"Cell"},{"issue":"11","key":"10.1016\/j.biopha.2023.114802_bib131","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.tibs.2008.08.002","article-title":"HIF-1 regulation: not so easy come, easy go","volume":"33","author":"Koh","year":"2008","journal-title":"Trends Biochem. Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib132","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s12079-020-00553-8","article-title":"HIF-hypoxia signaling in skeletal muscle physiology and fibrosis","volume":"14","author":"Valle-Tenney","year":"2020","journal-title":"J. Cell Commun. Signal."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib133","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1016\/S0014-5793(01)02833-2","article-title":"A non-hypoxic, ROS-sensitive pathway mediates TNF-\u03b1-dependent regulation of HIF-1\u03b1","volume":"505","author":"Haddad","year":"2001","journal-title":"FEBS Lett."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib134","doi-asserted-by":"crossref","first-page":"C392","DOI":"10.1152\/ajpcell.00125.2016","article-title":"The ubiquitin proteasome system in atrophying skeletal muscle: roles and regulation","volume":"311","author":"Bilodeau","year":"2016","journal-title":"Am. J. Physiol. -Cell Physiol."},{"key":"10.1016\/j.biopha.2023.114802_bib135","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1007\/978-981-13-1435-3_10","article-title":"Ubiquitin-proteasome pathway and muscle atrophy","author":"Khalil","year":"2018","journal-title":"Muscle Atrophy"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib136","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41392-020-0107-0","article-title":"The role of ubiquitination in tumorigenesis and targeted drug discovery","volume":"5","author":"Deng","year":"2020","journal-title":"Signal Transduct. Target. Ther."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib137","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14728222.2019.1615883","article-title":"Aberrant lipid metabolism as a therapeutic target in liver cancer","volume":"23","author":"Pope","year":"2019","journal-title":"Expert Opin. Ther. Targets"},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib138","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1038\/nrc.2016.84","article-title":"Oxygen availability and metabolic adaptations","volume":"16","author":"Nakazawa","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"41","key":"10.1016\/j.biopha.2023.114802_bib139","doi-asserted-by":"crossref","first-page":"16825","DOI":"10.1074\/jbc.R117.799973","article-title":"Oxygen availability and metabolic reprogramming in cancer","volume":"292","author":"Xie","year":"2017","journal-title":"J. Biol. Chem."},{"issue":"7184","key":"10.1016\/j.biopha.2023.114802_bib140","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nature06667","article-title":"Pyruvate kinase M2 is a phosphotyrosine-binding protein","volume":"452","author":"Christofk","year":"2008","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib141","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1016\/j.cell.2011.03.054","article-title":"Pyruvate kinase M2 is a PHD3-stimulated coactivator for hypoxia-inducible factor 1","volume":"145","author":"Luo","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.biopha.2023.114802_bib142","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.neuroscience.2011.11.060","article-title":"Hypoxic preconditioning attenuates global cerebral ischemic injury following asphyxial cardiac arrest through regulation of delta opioid receptor system","volume":"202","author":"Gao","year":"2012","journal-title":"Neuroscience"},{"key":"10.1016\/j.biopha.2023.114802_bib143","first-page":"1","article-title":"A cell model for evaluating mitochondrial damage in cardiomyocytes","author":"Zhang","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"key":"10.1016\/j.biopha.2023.114802_bib144","first-page":"347","article-title":"Regulation of metabolism by hypoxia-inducible factor 1","volume":"Vol. 76","author":"Semenza","year":"2011"},{"issue":"20","key":"10.1016\/j.biopha.2023.114802_bib145","doi-asserted-by":"crossref","first-page":"8117","DOI":"10.1158\/0008-5472.CAN-09-3871","article-title":"De novo lipogenesis protects cancer cells from free radicals and chemotherapeutics by promoting membrane lipid saturationlipogenesis promotes membrane lipid saturation","volume":"70","author":"Rysman","year":"2010","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib146","doi-asserted-by":"crossref","first-page":"68","DOI":"10.3390\/cancers12010068","article-title":"TCA cycle rewiring as emerging metabolic signature of hepatocellular carcinoma","volume":"12","author":"Todisco","year":"2019","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib147","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.celrep.2014.08.056","article-title":"Fatty acid uptake and lipid storage induced by HIF-1\u03b1 contribute to cell growth and survival after hypoxia-reoxygenation","volume":"9","author":"Bensaad","year":"2014","journal-title":"Cell Rep."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib148","doi-asserted-by":"crossref","first-page":"1930","DOI":"10.1016\/j.celrep.2014.08.028","article-title":"HIF-1-mediated suppression of acyl-CoA dehydrogenases and fatty acid oxidation is critical for cancer progression","volume":"8","author":"Huang","year":"2014","journal-title":"Cell Rep."},{"issue":"7381","key":"10.1016\/j.biopha.2023.114802_bib149","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1038\/nature10602","article-title":"Reductive glutamine metabolism by IDH1 mediates lipogenesis under hypoxia","volume":"481","author":"Metallo","year":"2012","journal-title":"Nature"},{"issue":"25","key":"10.1016\/j.biopha.2023.114802_bib150","doi-asserted-by":"crossref","first-page":"16767","DOI":"10.1074\/jbc.M901790200","article-title":"Genome-wide association of hypoxia-inducible factor (HIF)-1\u03b1 and HIF-2\u03b1 DNA binding with expression profiling of hypoxia-inducible transcripts","volume":"284","author":"Mole","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib151","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1016\/j.ccr.2012.09.020","article-title":"Phosphoglycerate mutase 1 coordinates glycolysis and biosynthesis to promote tumor growth","volume":"22","author":"Hitosugi","year":"2012","journal-title":"Cancer Cell"},{"key":"10.1016\/j.biopha.2023.114802_bib152","first-page":"1","article-title":"The multifaceted role of hypoxia\u2014inducible factor 1 (HIF1) in lipid metabolism","author":"Shen","year":"2017","journal-title":"Hypoxia Hum. Dis."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib153","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1165\/rcmb.2019-0008OC","article-title":"Glutamine metabolism is required for collagen protein synthesis in lung fibroblasts","volume":"61","author":"Hamanaka","year":"2019","journal-title":"Am. J. Respir. Cell Mol. Biol."},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib154","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/nrc.2016.71","article-title":"From Krebs to clinic: glutamine metabolism to cancer therapy","volume":"16","author":"Altman","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"9","key":"10.1016\/j.biopha.2023.114802_bib155","article-title":"Role of the HIF oxygen sensing pathway in cell defense and proliferation through the control of amino acid metabolism","volume":"1867","author":"Bouthelier","year":"2020","journal-title":"Biochim. Biophys. Acta (BBA)-Mol. Cell Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib156","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S1097-2765(03)00105-9","article-title":"An integrated stress response regulates amino acid metabolism and resistance to oxidative stress","volume":"11","author":"Harding","year":"2003","journal-title":"Mol. Cell"},{"issue":"8","key":"10.1016\/j.biopha.2023.114802_bib157","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.3390\/ijms20081888","article-title":"Transcriptional regulation factors of the human mitochondrial aspartate\/glutamate carrier gene, isoform 2 (SLC25A13): USF1 as basal factor and FOXA2 as activator in liver cells","volume":"20","author":"Convertini","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib158","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.cell.2017.02.004","article-title":"mTOR signaling in growth, metabolism, and disease","volume":"168","author":"Saxton","year":"2017","journal-title":"Cell"},{"issue":"23","key":"10.1016\/j.biopha.2023.114802_bib159","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1101\/gad.1256804","article-title":"Regulation of mTOR function in response to hypoxia by REDD1 and the TSC1\/TSC2 tumor suppressor complex","volume":"18","author":"Brugarolas","year":"2004","journal-title":"Genes Dev."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib160","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.molcel.2006.01.010","article-title":"Hypoxia-induced energy stress regulates mRNA translation and cell growth","volume":"21","author":"Liu","year":"2006","journal-title":"Mol. Cell"},{"issue":"49","key":"10.1016\/j.biopha.2023.114802_bib161","doi-asserted-by":"crossref","first-page":"35803","DOI":"10.1074\/jbc.M705231200","article-title":"Bnip3 mediates the hypoxia-induced inhibition on mammalian target of rapamycin by interacting with Rheb","volume":"282","author":"Li","year":"2007","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib162","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1442-2050.2011.01321.x","article-title":"Hypoxia suppresses E\u2010cadherin and enhances matrix metalloproteinase\u20102 expression favoring esophageal carcinoma migration and invasion via hypoxia inducible factor\u20101 alpha activation","volume":"26","author":"Jing","year":"2013","journal-title":"Dis. Esophagus"},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib163","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1038\/ng.3421","article-title":"NRF2 regulates serine biosynthesis in non\u2013small cell lung cancer","volume":"47","author":"DeNicola","year":"2015","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib164","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1038\/s41467-020-14746-7","article-title":"A serine\/threonine protein kinase encoding gene KERNEL NUMBER PER ROW6 regulates maize grain yield","volume":"11","author":"Jia","year":"2020","journal-title":"Nat. Commun."},{"issue":"22","key":"10.1016\/j.biopha.2023.114802_bib165","doi-asserted-by":"crossref","first-page":"6458","DOI":"10.1158\/0008-5472.CAN-16-1730","article-title":"Serine synthesis helps hypoxic cancer stem cells regulate redox","volume":"76","author":"Samanta","year":"2016","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib166","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/S0360-3016(01)01630-3","article-title":"Elevated tumor lactate concentrations predict for an increased risk of metastases in head-and-neck cancer","volume":"51","author":"Brizel","year":"2001","journal-title":"Int. J. Radiat. Oncol. * Biol. * Phys."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib167","first-page":"916","article-title":"High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers","volume":"60","author":"Walenta","year":"2000","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib168","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/jbmr.3908","article-title":"Lactate efflux from intervertebral disc cells is required for maintenance of spine health","volume":"35","author":"Silagi","year":"2020","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.biopha.2023.114802_bib169","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/B978-0-12-394316-3.00009-0","article-title":"The SLC16A family of monocarboxylate transporters (MCTs)\u2014physiology and function in cellular metabolism, pH homeostasis, and fluid transport","volume":"70","author":"Adijanto","year":"2012","journal-title":"Curr. Top. Membr."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib170","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.febslet.2010.11.009","article-title":"Lactate downregulates the glycolytic enzymes hexokinase and phosphofructokinase in diverse tissues from mice","volume":"585","author":"Leite","year":"2011","journal-title":"FEBS Lett."},{"key":"10.1016\/j.biopha.2023.114802_bib171","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.3389\/fonc.2019.01143","article-title":"Lactate in the regulation of tumor microenvironment and therapeutic approaches","volume":"9","author":"de la Cruz-L\u00f3pez","year":"2019","journal-title":"Front. Oncol."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib172","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0167-4781(01)00359-1","article-title":"Identification of an additional hypoxia responsive element in the glyceraldehyde-3-phosphate dehydrogenase gene promoter","volume":"1574","author":"Lu","year":"2002","journal-title":"Biochim. Biophys. Acta (BBA)-Gene Struct. Expr."},{"key":"10.1016\/j.biopha.2023.114802_bib173","series-title":"Lactate activates HIF-1 in oxidative but not in Warburg-phenotype human tumor cells","author":"De Saedeleer","year":"2012"},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib174","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41584-021-00621-2","article-title":"The role of HIF proteins in maintaining the metabolic health of the intervertebral disc","volume":"17","author":"Silagi","year":"2021","journal-title":"Nat. Rev. Rheumatol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib175","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1111\/cas.13483","article-title":"Regulatory mechanisms of hypoxia-inducible factor 1 activity: Two decades of knowledge","volume":"109","author":"Koyasu","year":"2018","journal-title":"Cancer Sci."},{"key":"10.1016\/j.biopha.2023.114802_bib176","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12943-019-1089-9","article-title":"Role of hypoxia in cancer therapy by regulating the tumor microenvironment","volume":"18","author":"Jing","year":"2019","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.biopha.2023.114802_bib177","doi-asserted-by":"crossref","first-page":"2813","DOI":"10.3390\/cancers13112813","article-title":"An overview of the recent development of anticancer agents targeting the HIF-1 transcription factor","volume":"13","author":"Shirai","year":"2021","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib178","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1080\/17460441.2019.1613370","article-title":"The transcriptional factors HIF-1 and HIF-2 and their novel inhibitors in cancer therapy","volume":"14","author":"Albadari","year":"2019","journal-title":"Expert Opin. Drug Discov."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib179","doi-asserted-by":"crossref","first-page":"410","DOI":"10.3390\/cancers13030410","article-title":"Specific inhibition of HIF activity: Can peptides lead the way?","volume":"13","author":"Mylonis","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.biopha.2023.114802_bib180","doi-asserted-by":"crossref","first-page":"22313","DOI":"10.18632\/oncotarget.16224","article-title":"Anthracyclines suppress pheochromocytoma cell characteristics, including metastasis, through inhibition of the hypoxia signaling pathway","volume":"8","author":"Pang","year":"2017","journal-title":"Oncotarget"},{"issue":"50","key":"10.1016\/j.biopha.2023.114802_bib181","doi-asserted-by":"crossref","first-page":"19579","DOI":"10.1073\/pnas.0809763105","article-title":"Digoxin and other cardiac glycosides inhibit HIF-1\u03b1 synthesis and block tumor growth","volume":"105","author":"Zhang","year":"2008","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib182","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1096\/fj.09-145664","article-title":"Digoxin inhibits retinal ischemia-induced HIF-1\u03b1 expression and ocular neovascularization","volume":"24","author":"Yoshida","year":"2010","journal-title":"The FASEB J."},{"issue":"19","key":"10.1016\/j.biopha.2023.114802_bib183","doi-asserted-by":"crossref","first-page":"6845","DOI":"10.1158\/0008-5472.CAN-04-2116","article-title":"Schedule-dependent inhibition of hypoxia-inducible factor-1\u03b1 protein accumulation, angiogenesis, and tumor growth by topotecan in U251-HRE glioblastoma xenografts","volume":"64","author":"Rapisarda","year":"2004","journal-title":"Cancer Res."},{"issue":"11","key":"10.1016\/j.biopha.2023.114802_bib184","doi-asserted-by":"crossref","first-page":"2440","DOI":"10.3390\/cells9112440","article-title":"Calcitriol suppresses HIF-1 and HIF-2 transcriptional activity by reducing HIF-1\/2\u03b1 protein levels via a VDR-independent mechanism","volume":"9","author":"Gkotinakou","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.biopha.2023.114802_bib185","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.172961","article-title":"YC-1 potentiates the antitumor activity of gefitinib by inhibiting HIF-1\u03b1 and promoting the endocytic trafficking and degradation of EGFR in gefitinib-resistant non-small-cell lung cancer cells","volume":"874","author":"Hu","year":"2020","journal-title":"Eur. J. Pharmacol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib186","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/jcp.24813","article-title":"A group of novel HIF\u20101\u03b1 inhibitors, glyceollins, blocks HIF\u20101\u03b1 synthesis and decreases its stability via inhibition of the PI3K\/AKT\/mTOR pathway and Hsp90 binding","volume":"230","author":"Lee","year":"2015","journal-title":"J.\u00a0Cell.\u00a0Physiol."},{"issue":"7627","key":"10.1016\/j.biopha.2023.114802_bib187","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/nature19796","article-title":"Targeting renal cell carcinoma with a HIF-2 antagonist","volume":"539","author":"Chen","year":"2016","journal-title":"Nature"},{"issue":"28","key":"10.1016\/j.biopha.2023.114802_bib188","doi-asserted-by":"crossref","first-page":"10418","DOI":"10.1021\/ja402993u","article-title":"A cyclic peptide inhibitor of HIF-1 heterodimerization that inhibits hypoxia signaling in cancer cells","volume":"135","author":"Miranda","year":"2013","journal-title":"J. Am. Chem. Soc."},{"issue":"7","key":"10.1016\/j.biopha.2023.114802_bib189","doi-asserted-by":"crossref","first-page":"jcs225698","DOI":"10.1242\/jcs.225698","article-title":"ERK1\/2 phosphorylates HIF-2\u03b1 and regulates its activity by controlling its CRM1-dependent nuclear shuttling","volume":"132","author":"Gkotinakou","year":"2019","journal-title":"J. Cell Sci."},{"issue":"2","key":"10.1016\/j.biopha.2023.114802_bib190","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1242\/jcs.195339","article-title":"Mortalin-mediated and ERK-controlled targeting of HIF-1\u03b1 to mitochondria confers resistance to apoptosis under hypoxia","volume":"130","author":"Mylonis","year":"2017","journal-title":"J. Cell Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib191","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.bbrc.2010.06.038","article-title":"The dietary flavonoid kaempferol effectively inhibits HIF-1 activity and hepatoma cancer cell viability under hypoxic conditions","volume":"398","author":"Mylonis","year":"2010","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.biopha.2023.114802_bib192","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1007\/s10637-010-9493-4","article-title":"A Phase II trial of 17-allylamino, 17-demethoxygeldanamycin (17-AAG, tanespimycin) in patients with metastatic melanoma","volume":"30","author":"Pacey","year":"2012","journal-title":"Invest. New Drugs"},{"key":"10.1016\/j.biopha.2023.114802_bib193","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1007\/s00018-018-2985-7","article-title":"HIF-1\u03b1-derived cell-penetrating peptides inhibit ERK-dependent activation of HIF-1 and trigger apoptosis of cancer cells under hypoxia","volume":"76","author":"Karagiota","year":"2019","journal-title":"Cell. Mol. Life Sci."},{"issue":"39","key":"10.1016\/j.biopha.2023.114802_bib194","doi-asserted-by":"crossref","first-page":"15602","DOI":"10.1073\/pnas.1312473110","article-title":"Protein domain mimetics as in vivo modulators of hypoxia-inducible factor signaling","volume":"110","author":"Kushal","year":"2013","journal-title":"Proc. Natl. Acad. Sci."},{"issue":"21","key":"10.1016\/j.biopha.2023.114802_bib195","doi-asserted-by":"crossref","first-page":"7531","DOI":"10.1073\/pnas.1402393111","article-title":"In vivo modulation of hypoxia-inducible signaling by topographical helix mimetics","volume":"111","author":"Lao","year":"2014","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2023.114802_bib196","first-page":"125","article-title":"Aryl hydrocarbon receptor activation by aminoflavone: New molecular target for renal cancer treatment","volume":"41","author":"Callero","year":"2012","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.biopha.2023.114802_bib197","doi-asserted-by":"crossref","first-page":"6837","DOI":"10.1158\/0008-5472.CAN-10-1075","article-title":"Aminoflavone, a ligand of the aryl hydrocarbon receptor, inhibits HIF-1alpha expression in an AhR-independent fashion","volume":"70","author":"Terzuoli","year":"2010","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib198","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s00280-013-2362-z","article-title":"Pilot trial of EZN-2968, an antisense oligonucleotide inhibitor of hypoxia-inducible factor-1 alpha (HIF-1alpha), in patients with refractory solid tumors","volume":"73","author":"Jeong","year":"2014","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114802_bib199","article-title":"Epidermal growth factor receptor inhibition reduces angiogenesis via hypoxia-inducible factor-1alpha and Notch1 in head neck squamous cell carcinoma","volume":"10","author":"Wang","year":"2015","journal-title":"PLoS ONE"},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib200","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.canlet.2012.02.012","article-title":"The anti-EGFR antibody cetuximab sensitizes human head and neck squamous cell carcinoma cells to radiation in part through inhibiting radiation-induced upregulation of HIF-1\u03b1","volume":"322","author":"Lu","year":"2012","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.114802_bib201","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1083\/jcb.201004145","article-title":"Microtubule disruption targets HIF-1alpha mRNA to cytoplasmic P-bodies for translational repression","volume":"192","author":"Carbonaro","year":"2011","journal-title":"J. Cell Biol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114802_bib202","first-page":"L913","article-title":"Exposure of differentiated airway smooth muscle cells to serum stimulates both induction of hypoxia-inducible factor-1\u03b1 and airway responsiveness to ACh","volume":"293","author":"Chachami","year":"2007","journal-title":"Am.\u00a0J.\u00a0Physiol.\u00a0Lung Cell\u00a0Mol. Physiol."},{"issue":"13","key":"10.1016\/j.biopha.2023.114802_bib203","doi-asserted-by":"crossref","first-page":"3026","DOI":"10.1016\/j.bmcl.2017.05.024","article-title":"Synthesis and biological evaluation of kresoxim-methyl analogues as novel inhibitors of hypoxia-inducible factor (HIF)-1 accumulation in cancer cells","volume":"27","author":"Lee","year":"2017","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2023.114802_bib204","doi-asserted-by":"crossref","first-page":"11870","DOI":"10.1021\/ja104739t","article-title":"Identification of HSP60 as a primary target of o-carboranylphenoxyacetanilide, an HIF-1\u03b1 Inhibitor","volume":"132","author":"Ban","year":"2010","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.biopha.2023.114802_bib205","first-page":"1557","article-title":"Curcumin inhibits hypoxia-induced angiogenesis via downregulation of HIF-1","volume":"15","author":"Bae","year":"2006","journal-title":"Oncol Rep"},{"key":"10.1016\/j.biopha.2023.114802_bib206","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1124\/mol.106.025817","article-title":"Curcumin inhibits hypoxia-inducible factor-1 by degrading aryl hydrocarbon receptor nuclear translocator: a mechanism of tumor growth inhibition","volume":"70","author":"Choi","year":"2006","journal-title":"Mol Pharmacol"},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib207","first-page":"1198","article-title":"Inhibition of HIF-1\u03b1 by PX-478 suppresses tumor growth of esophageal squamous cell cancer in vitro and in vivo","volume":"7","author":"Zhu","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib208","doi-asserted-by":"crossref","first-page":"3155","DOI":"10.1016\/j.bmcl.2014.04.116","article-title":"Marine spongian sesquiterpene phenols, dictyoceratin-C and smenospondiol, display hypoxia-selective growth inhibition against cancer cells","volume":"24","author":"Arai","year":"2014","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.biopha.2023.114802_bib209","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1124\/mol.62.5.975","article-title":"Reduction of hypoxiainduced transcription through the repression of hypoxia-inducible factor-1alpha\/aryl hydrocarbon receptor nuclear translocator DNA binding by the 90-kDa heat-shock protein inhibitor radicicol","volume":"62","author":"Hur","year":"2002","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114802_bib210","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1111\/j.1349-7006.2001.tb02159.x","article-title":"A radicicol derivative, KF58333, inhibits expression of hypoxia-inducible factor-1\u03b1 and vascular endothelial growth factor, angiogenesis and growth of human breast cancer xenografts","volume":"92","author":"Kurebayashi","year":"2001","journal-title":"Jpn J .Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib211","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1042\/BJ20041355","article-title":"Epolactaene binds human Hsp60 Cys442 resulting in the inhibition of chaperone activity","volume":"387","author":"Nagumo","year":"2005","journal-title":"Biochem. J."},{"key":"10.1016\/j.biopha.2023.114802_bib212","doi-asserted-by":"crossref","first-page":"35863","DOI":"10.1074\/jbc.M005643200","article-title":"The role of mitochondria in the regulation of hypoxia-inducible factor 1 expression during hypoxia","volume":"275","author":"Agani","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114802_bib213","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1248\/bpb.29.1344","article-title":"Inhibition of angiogenesis and HIF-1\u03b1 activity by antimycin A1","volume":"29","author":"Maeda","year":"2006","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.biopha.2023.114802_bib214","doi-asserted-by":"crossref","first-page":"20989","DOI":"10.1074\/jbc.M117.812925","article-title":"The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals","volume":"292","author":"Ma","year":"2017","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114802_bib215","doi-asserted-by":"crossref","DOI":"10.1111\/jpi.12739","article-title":"Enhanced anti-angiogenic activity of novel melatonin-like agents","author":"Hwang","year":"2021","journal-title":"J. Pineal Res."},{"key":"10.1016\/j.biopha.2023.114802_bib216","doi-asserted-by":"crossref","first-page":"347","DOI":"10.2174\/1871520615666150511094201","article-title":"Melatonin regulates angiogenic factors under hypoxia in breast cancer cell lines","volume":"16","author":"Jardim-Perassi","year":"2016","journal-title":"Anticancer Agents Med. Chem."},{"key":"10.1016\/j.biopha.2023.114802_bib217","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.canlet.2017.10.041","article-title":"Apigenin: a dietary flavonoid with diverse anticancer properties","volume":"413","author":"Madunic","year":"2018","journal-title":"Cancer Lett."},{"key":"10.1016\/j.biopha.2023.114802_bib218","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00280-012-1972-1","article-title":"Phase I study of lonafarnib (SCH66336) in combination with trastuzumab plus paclitaxel in Her2\/neu overexpressing breast cancer: EORTC study 16023","volume":"71","author":"Milojkovic Kerklaan","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114802_bib219","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1517\/13543784.15.6.709","article-title":"Lonafarnib in cancer therapy","volume":"15","author":"Morgillo","year":"2006","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.biopha.2023.114802_bib220","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1038\/86507","article-title":"Histone deacetylases induce angiogenesis by negative regulation of tumor suppressor genes","volume":"7","author":"Kim","year":"2001","journal-title":"Nat. Med."},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib221","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.1093\/jnen\/nlx088","article-title":"LBH589 inhibits glioblastoma growth and angiogenesis through suppression of HIF-1\u03b1 expression","volume":"76","author":"Yao","year":"2017","journal-title":"J. Neuropathol. Exp. Neurol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114802_bib222","doi-asserted-by":"crossref","first-page":"e2843","DOI":"10.1038\/cddis.2017.235","article-title":"The novel hypoxia-inducible factor-1\u03b1 inhibitor IDF-11774 regulates cancer metabolism, thereby suppressing tumor growth","volume":"8","author":"Ban","year":"2017","journal-title":"Cell Death Dis."},{"issue":"3","key":"10.1016\/j.biopha.2023.114802_bib223","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/jcb.24390","article-title":"Recent agents targeting HIF\u20101\u03b1 for cancer therapy","volume":"114","author":"Hu","year":"2013","journal-title":"J.\u00a0Cell.\u00a0Biochem."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib224","first-page":"1","article-title":"Tetrathiomolybdate inhibits mitochondrial complex IV and mediates degradation of hypoxia-inducible factor-1\u03b1 in cancer cells","volume":"5","author":"Kim","year":"2015","journal-title":"Sci.\u00a0Rep."},{"issue":"42","key":"10.1016\/j.biopha.2023.114802_bib225","doi-asserted-by":"crossref","first-page":"17910","DOI":"10.1073\/pnas.0909353106","article-title":"Acriflavine inhibits HIF-1 dimerization, tumor growth, and vascularization","volume":"106","author":"Lee","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.biopha.2023.114802_bib226","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.2174\/0929867327666200908114411","article-title":"Repurposing of Acriflavine to target Chronic Myeloid Leukemia treatment","volume":"28","author":"Nehme","year":"2020","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.biopha.2023.114802_bib227","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00109-016-1498-9","article-title":"The HIF-1 antagonist acriflavine: Visualization in retina and suppression of ocular neovascularization","volume":"95","author":"Zeng","year":"2017","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.biopha.2023.114802_bib228","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1002\/(SICI)1097-0142(19980115)82:2<301::AID-CNCR8>3.0.CO;2-T","article-title":"A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: An Eastern Cooperative Oncology Group Study (E1587)","volume":"82","author":"Chang","year":"1998","journal-title":"Cancer"},{"key":"10.1016\/j.biopha.2023.114802_bib229","doi-asserted-by":"crossref","first-page":"4022","DOI":"10.1021\/acs.jmedchem.9b02039","article-title":"Design, synthesis, and conformation-activity study of unnatural bridged bicyclic depsipeptides as highly potent hypoxia inducible factor-1 inhibitors and antitumor agents","volume":"63","author":"Koike","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.biopha.2023.114802_bib230","doi-asserted-by":"crossref","first-page":"34866","DOI":"10.1074\/jbc.M112.374587","article-title":"Anthracycline inhibits recruitment of hypoxia-inducible transcription factors and suppresses tumor cell migration and cardiac angiogenic response in the host","volume":"287","author":"Tanaka","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.biopha.2023.114802_bib231","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1158\/0008-5472.CAN-06-2722","article-title":"Suppression of the hypoxia-inducible factor-1 response in cervical carcinoma xenografts by proteasome inhibitors","volume":"67","author":"Birle","year":"2007","journal-title":"Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib232","doi-asserted-by":"crossref","first-page":"10280","DOI":"10.18632\/oncotarget.2163","article-title":"Targeting hypoxia-inducible factor-1alpha (HIF-1alpha) in combination with antiangiogenic therapy: A phase I trial of bortezomib bevacizumab","volume":"5","author":"Falchook","year":"2014","journal-title":"Oncotarget"},{"key":"10.1016\/j.biopha.2023.114802_bib233","doi-asserted-by":"crossref","first-page":"808","DOI":"10.1158\/1078-0432.CCR-14-2810","article-title":"Translational impact of nanoparticle-drug conjugate CRLX101 with or without bevacizumab in advanced ovarian cancer","volume":"21","author":"Pham","year":"2015","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.biopha.2023.114802_bib234","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1093\/annonc\/mdx493","article-title":"A randomized phase II trial of CRLX101 in combination with bevacizumab versus standard of care in patients with advanced renal cell carcinoma","volume":"28","author":"Voss","year":"2017","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.biopha.2023.114802_bib235","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173716","article-title":"Metformin ameliorates brain damage caused by cardiopulmonary resuscitation via targeting endoplasmic reticulum stress-related proteins GRP78 and XBP1","volume":"891","author":"Chuan","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.biopha.2023.114802_bib236","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.02242","article-title":"Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis","volume":"3","author":"Wheaton","year":"2014","journal-title":"eLife"},{"key":"10.1016\/j.biopha.2023.114802_bib237","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1158\/0008-5472.CAN-03-3139","article-title":"Topoisomerase I-mediated inhibition of hypoxia-inducible factor 1: Mechanism and therapeutic implications","volume":"64","author":"Rapisarda","year":"2004","journal-title":"Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib238","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1158\/1535-7163.MCT-08-0944","article-title":"Targeting both HIF-1 and HIF-2 in human colon cancer cells improves tumor response to sunitinib treatment","volume":"8","author":"Burkitt","year":"2009","journal-title":"Mol.\u00a0Cancer Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.114802_bib239","article-title":"YAP\/TAZ and ATF4 drive resistance to Sorafenib in hepatocellular carcinoma by preventing ferroptosis","volume":"13","author":"Gao","year":"2021","journal-title":"EMBO Mol.\u00a0Med."},{"key":"10.1016\/j.biopha.2023.114802_bib240","first-page":"363","article-title":"Phosphatidylinositol 3-kinase signaling controls levels of hypoxia-inducible factor 1","volume":"12","author":"Jiang","year":"2001","journal-title":"Cell Growth Differ"},{"key":"10.1016\/j.biopha.2023.114802_bib241","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1038\/nm1052","article-title":"mTOR inhibition reverses Akt-dependent prostate intraepithelial neoplasia through regulation of apoptotic and HIF- 1-dependent pathways","volume":"10","author":"Majumder","year":"2004","journal-title":"Nat. Med."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib242","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1440-1827.2008.02320.x","article-title":"Therapeutic strategy targeting the mTOR\u2013HIF\u20101\u03b1\u2013VEGF pathway in ovarian clear cell adenocarcinoma","volume":"59","author":"Miyazawa","year":"2009","journal-title":"Pathol. Int."},{"key":"10.1016\/j.biopha.2023.114802_bib243","doi-asserted-by":"crossref","first-page":"5364","DOI":"10.1021\/acs.orglett.5b02718","article-title":"Structure elucidation of verucopeptin, a HIF-1 inhibitory polyketide-hexapeptide hybrid metabolite from an actinomycete","volume":"17","author":"Yoshimura","year":"2015","journal-title":"Org. Lett."},{"key":"10.1016\/j.biopha.2023.114802_bib244","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1007\/s10637-010-9455-x","article-title":"A phase II study of 2-methoxyestradiol (2ME2) Nano- Crystal \u00ae dispersion (NCD) in patients with taxane-refractory, metastatic castrate-resistant prostate cancer (CRPC)","volume":"29","author":"Harrison","year":"2011","journal-title":"Invest. N. Drugs"},{"key":"10.1016\/j.biopha.2023.114802_bib245","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S0014-5793(99)01359-9","article-title":"Hypoxia-induced activation of HIF-1: Role of HIF-1\u03b1-Hsp90 interaction","volume":"460","author":"Minet","year":"1999","journal-title":"FEBS Lett."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib246","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/S0006-291X(02)02787-0","article-title":"Inhibition of hypoxia-induced angiogenesis by FK228, a specific histone deacetylase inhibitor, via suppression of HIF-1\u03b1 activity","volume":"300","author":"Lee","year":"2003","journal-title":"Biochem. Biophys. Res."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib247","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ccr.2004.06.009","article-title":"Small molecule blockade of transcriptional coactivation of the hypoxia-inducible factor pathway","volume":"6","author":"Kung","year":"2004","journal-title":"Cancer Cell"},{"issue":"8","key":"10.1016\/j.biopha.2023.114802_bib248","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1080\/15384047.2020.1763147","article-title":"Chetomin, a Hsp90\/HIF1\u03b1 pathway inhibitor, effectively targets lung cancer stem cells and non-stem cells","volume":"21","author":"Min","year":"2020","journal-title":"Cancer Biol. Ther."},{"issue":"10","key":"10.1016\/j.biopha.2023.114802_bib249","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/s41429-021-00451-0","article-title":"Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy","volume":"74","author":"Ikeda","year":"2021","journal-title":"J. Antibiot."},{"key":"10.1016\/j.biopha.2023.114802_bib250","first-page":"1","article-title":"Screening of phytochemicals effective on relieving cancer cachexia in cisplatin-induced in vitro sarcopenia model","author":"Lee","year":"2022","journal-title":"Mol. Cell. Toxicol."},{"issue":"17","key":"10.1016\/j.biopha.2023.114802_bib251","doi-asserted-by":"crossref","first-page":"11142","DOI":"10.1074\/jbc.M808348200","article-title":"SEPT9_v1 up-regulates hypoxia-inducible factor 1 by preventing its RACK1-mediated degradation","volume":"284","author":"Amir","year":"2009","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.biopha.2023.114802_bib252","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4062\/biomolther.2012.20.1.019","article-title":"Cyclic peptides as therapeutic agents and biochemical tools","volume":"20","author":"Joo","year":"2012","journal-title":"Biomol. Ther."},{"issue":"5","key":"10.1016\/j.biopha.2023.114802_bib253","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/molecules24050927","article-title":"Recent advances in cell penetrating peptide-based anticancer therapies","volume":"24","author":"Habault","year":"2019","journal-title":"Molecules"}],"container-title":["Biomedicine &amp; Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223005929?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223005929?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T17:48:20Z","timestamp":1780336100000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223005929"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7]]},"references-count":254,"alternative-id":["S0753332223005929"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114802","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Understanding the relationship between cancer associated cachexia and hypoxia-inducible factor-1","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114802","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114802"}}